Currus Biologics is developing its proprietary BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) platform to unlock CAR T-cell therapy for solid tumours
Currus Biologics is developing its proprietary BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) platform to unlock CAR T-cell therapy for solid tumours. The BEAT technology provides a cost-effective, flexible add-on, enabling partners to unlock their technology and deliver life-changing outcomes for patients.